Factors Influencing Physician Recommendation for Imatinib Mesylate in Chronic Phase Chronic Myeloid Leukemia
- PDF / 15,073,980 Bytes
- 13 Pages / 648 x 864 pts Page_size
- 64 Downloads / 184 Views
141
Factors Influencing Physician Recommendation for Imatinib Mesylate in Chronic Phase Chronic Myeloid Leukemia*
Shrividya lyer, PhD Clinical and Administrative Pharmacy. University of Iowa WilliOm R. Doucetter PhD Associate Professoc Clinical and Administrative Pharmacy, University of Iowa
Key Words Imatinib mesylate; Chronic myeloid leukemia; Physician recommendation; Adoption ofdrugs Correspondante Address William Doucette, University of Iowa, 5518 PHAR, Iowa City, IA 52242. (email:[email protected]). 'This material was presented as a poster session at International Society for Pharmacoeconomics and Outcomes Research, Arlington. Virginia, May 17,2004.
Objective: The objective of this study was to identifi significant influences on physician recommendation for imatinib mesylate in chronic phase CML patients. Methods: Data were collected via a mail and Web suwey of a random sample of 1,100 hematdogistdoncdogists. Physicians' recommendations for imatinib were measured with a visual analog scale in response to a series of clinical vignettes. Linear multiple regression was used to test the model, with physician recommendations as the dependent variable. The independent variables included treatment characteristics, communication channels, physician characteristics, social sys-
BACKGROUND Drug therapy is perhaps the most active area of change in medicine (1).The 20th century in particular may be considered as a period of rapid and significant drug development (2). New drugs are developed to replace or to complement existing medications, to treat emerging or previously untreatable diseases, or for any combination of these uses (3). Practicing physicians are faced with the difficult task of keeping up with rapid changes in drug treatments (1).The time involved to achieve full adoption of new drug treatments is a problem in medicine in general and specifically in cancer. Perhaps in cancer more than any other disease, state-of-the art therapy is defined through clinical trial results (4). Chronic myeloid leukemia (CML) or cancer of white blood cells is one type of cancer for which treatment strategies have changed drastically with time. Prior to 2001, allogeneic stem cell transplantation (alIoSCT) and interferon-a were the two most commonly used therapies for chronic CML. In May 2001, the Food and Drug Administration (FDA) approved imatinib mesylate (trade name
tem characteristics, and control variables. Results: A total of 305 responses was received, giving a response rate of 29%. The regression model was found to be significant.Perceived relative advantages in eficacr, peer influence, past experience, and academic affiliation were significant positive influences and transplant specialty was a significant negative influence on physician recommendation for imatinib mesylate in patients with chronic phase CML. Conclusion: Treatment characteristics,peer influence, and physician specialty had significant influences on physician recommendation for imatinib maylate.
GLEEVEC) for patients with chronic phase CML w
Data Loading...
